CC1007对宫颈癌顺铂化疗增敏作用的研究
发布时间：2018-11-25 22:39
【摘要】：目的 研究新型小分子化合物CC1007与顺铂联合使用对宫颈癌细胞化疗效果的影响及其可能的分子机制。 方法 1.四甲基偶氮唑蓝(MTT)比色法检测对照组、CC1007单药组、顺铂单药组及CC1007+顺铂联合用药组作用48小时对体外培养的人宫颈癌细胞株HeLa、Caski增殖的抑制效应,计算药物的半抑制率(IC50),并绘制浓度-抑制率曲线。实验重复3次。 2.Western blot检测对照组、CC1007单药组、顺铂单药组及CC1007+顺铂联合用药组作用24小时凋亡相关蛋白Nur77的表达。实验重复3次。 3.对实验数据进行统计学分析。 结果 1.MTT实验结果显示CC1007及顺铂均对宫颈癌细胞HeLa、 Caski有抑制作用,且呈浓度依赖性,差异有统计学意义(P0.05)。当两种药物联合作用时,抑制作用更加明显。在HeLa细胞中,顺铂的IC50由单药应用时的1.13μg/L降为联合应用时的0.520μg/L；在Caski细胞中,顺铂的IC50由单药应用时的1.55μg/L降为联合应用时的0.507μg/L,差异有统计学意义(P0.05)。两者联合应用时可发挥协同效应。 2. Western blot实验结果显示在HeLa细胞中,顺铂单药组及CC1007+顺铂联合用药组Nur77表达较对照组均升高,差异有统计学意义(P0.05)；顺铂单药组及CC1007+顺铂联合用药组之间Nur77的表达差异有统计学意义(P0.05)。在Caski细胞中,CC1007单药组、顺铂单药组及CC1007+顺铂联合用药组Nur77的表达较对照组均升高,差异有统计学意义(P0.05)；顺铂单药组及CC1007+顺铂联合用药组之间Nur77的表达差异有统计学意义(P0.05)。 结论 1.CC1007与顺铂均对人宫颈癌细胞株有抑制作用,且呈浓度依赖性,CC1007可增加人宫颈癌细胞株对顺铂的敏感性,两者联合作用可发挥协同效应。 2.在人宫颈癌细胞株HeLa、Caski中,顺铂可上调Nur77的表达,与CC1007联合应用,Nur77表达明显升高,这可能是CC1007与顺铂发挥协同效应的分子机制。
[Abstract]:Objective to study the effect of CC1007 combined with cisplatin on the chemotherapeutic effect of cervical cancer cells and its possible molecular mechanism. Method 1. The inhibitory effects of (MTT) colorimetric assay on the proliferation of human cervical cancer cell line HeLa,Caski in vitro were detected by (MTT) colorimetric assay in the control group, single CC1007 group, cisplatin group and CC1007 cisplatin group for 48 hours. The semi-inhibition rate (IC50) of the drug was calculated and the concentration-inhibition rate curve was drawn. The experiment was repeated three times. 2.Western blot was used to detect the expression of apoptosis-related protein (Nur77) in control group, CC1007 group, cisplatin group and CC1007 cisplatin group. The experiment was repeated three times. 3. The experimental data were analyzed statistically. Results 1.MTT results showed that both CC1007 and cisplatin could inhibit HeLa, Caski of cervical cancer cells in a dose-dependent manner, and the difference was statistically significant (P0.05). When the two drugs combined, the inhibitory effect was more obvious. In HeLa cells, the IC50 of cisplatin decreased from 1.13 渭 g / L to 0.520 渭 g / L in combination. In Caski cells, the IC50 of cisplatin decreased from 1.55 渭 g / L to 0.507 渭 g / L (P0.05). The synergistic effect can be brought into play when the two are applied in combination. 2. Western blot results showed that in HeLa cells, the Nur77 expression in cisplatin monotherapy group and CC1007 cisplatin combination group were higher than that in control group (P0.05). There was significant difference in the expression of Nur77 between cisplatin monotherapy group and CC1007 cisplatin combination group (P0.05). In Caski cells, the expression of Nur77 in CC1007 monotherapy group, cisplatin monotherapy group and CC1007 cisplatin combination group were significantly higher than that in control group (P0.05). There was significant difference in the expression of Nur77 between cisplatin monotherapy group and CC1007 cisplatin combination group (P0.05). Conclusion both 1.CC1007 and cisplatin can inhibit human cervical cancer cell line in a concentration-dependent manner. CC1007 can increase the sensitivity of human cervical cancer cell line to cisplatin. 2. In human cervical cancer cell line HeLa,Caski, cisplatin can up-regulate the expression of Nur77, and when combined with CC1007, the expression of Nur77 is significantly increased, which may be the molecular mechanism of synergistic effect of CC1007 and cisplatin.
【学位授予单位】：中南大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.33
本文编号：2357571
[Abstract]:Objective to study the effect of CC1007 combined with cisplatin on the chemotherapeutic effect of cervical cancer cells and its possible molecular mechanism. Method 1. The inhibitory effects of (MTT) colorimetric assay on the proliferation of human cervical cancer cell line HeLa,Caski in vitro were detected by (MTT) colorimetric assay in the control group, single CC1007 group, cisplatin group and CC1007 cisplatin group for 48 hours. The semi-inhibition rate (IC50) of the drug was calculated and the concentration-inhibition rate curve was drawn. The experiment was repeated three times. 2.Western blot was used to detect the expression of apoptosis-related protein (Nur77) in control group, CC1007 group, cisplatin group and CC1007 cisplatin group. The experiment was repeated three times. 3. The experimental data were analyzed statistically. Results 1.MTT results showed that both CC1007 and cisplatin could inhibit HeLa, Caski of cervical cancer cells in a dose-dependent manner, and the difference was statistically significant (P0.05). When the two drugs combined, the inhibitory effect was more obvious. In HeLa cells, the IC50 of cisplatin decreased from 1.13 渭 g / L to 0.520 渭 g / L in combination. In Caski cells, the IC50 of cisplatin decreased from 1.55 渭 g / L to 0.507 渭 g / L (P0.05). The synergistic effect can be brought into play when the two are applied in combination. 2. Western blot results showed that in HeLa cells, the Nur77 expression in cisplatin monotherapy group and CC1007 cisplatin combination group were higher than that in control group (P0.05). There was significant difference in the expression of Nur77 between cisplatin monotherapy group and CC1007 cisplatin combination group (P0.05). In Caski cells, the expression of Nur77 in CC1007 monotherapy group, cisplatin monotherapy group and CC1007 cisplatin combination group were significantly higher than that in control group (P0.05). There was significant difference in the expression of Nur77 between cisplatin monotherapy group and CC1007 cisplatin combination group (P0.05). Conclusion both 1.CC1007 and cisplatin can inhibit human cervical cancer cell line in a concentration-dependent manner. CC1007 can increase the sensitivity of human cervical cancer cell line to cisplatin. 2. In human cervical cancer cell line HeLa,Caski, cisplatin can up-regulate the expression of Nur77, and when combined with CC1007, the expression of Nur77 is significantly increased, which may be the molecular mechanism of synergistic effect of CC1007 and cisplatin.
【学位授予单位】：中南大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.33
【参考文献】
相关期刊论文 前1条
1 ;Induction of apoptosis by TPA and VP-16 is through translocation of TR3[J];World Journal of Gastroenterology;2002年03期
相关博士学位论文 前1条
1 柴小山;NKL30抑制宫颈癌机制探讨[D];中南大学;2013年
，本文编号：2357571
本文链接：https://www.wllwen.com/yixuelunwen/fuchankeerkelunwen/2357571.html
最近更新
教材专著
